Intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2 booster vaccine, third dose, SAR-CoV2, older adult
Conditions
Interventions
0.1 ml mRNA vaccine intradermal injection. Antibody levels are followed at 2-4 week and 12+/- weeks. Adverse event is followed for 7 days after injection ,0.3-0.5 ml mRNA vaccine intramuscular injecti
Experimental Biological/Vaccine,Active Comparator Biological/Vaccine
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged 65 years old or more. 2. Having a 2-dose primary series of ChAdOx1 (AstraZeneca) vaccine for 12-24 weeks. 3. Stable and well-controlled chronic diseases. 4. Ability to understand and communicate in Thai language. 5. Ability to attend the appointment. 6.Ability to give informed consent
Exclusion criteria
Exclusion criteria: 1. Having a history of anaphylaxis to drug or other vaccines. 2. Having a previous history of Covid-19 infection or high-risk of Covid-19 infection. 3. Having any type of vaccination 2 week before the recruitment. 4. Having any type of immunodeficiency. 5. Taking any type of immunosuppressive agent or cytotoxic drug. 6. No acute illness or acute inflammation. 7. Having blood transfusion or other blood products, immunoglobulin, antiviral agent, or antibody within previous 90 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vaccine adverse event 7 days number of adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| SARSCov-2 IgG 1 day AU/ml,T cell response 1 day T cell Elispot,Neutralizing antibody assay, Focus reduction neutralization test 1 day percent foci reduction, inhibitory concentration at 50% | — |
Countries
Thailand
Contacts
Public ContactPrasert Assantachai
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed